ID

13304

Description

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations; ODM derived from: https://clinicaltrials.gov/show/NCT00203034

Lien

https://clinicaltrials.gov/show/NCT00203034

Mots-clés

  1. 01/02/2016 01/02/2016 -
Téléchargé le

1 février 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :


Aucun commentaire

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Parkinson's Disease NCT00203034

Eligibility Parkinson's Disease NCT00203034

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
men and women with idiopathic parkinson's disease whose diagnosis is confirmed by at least two of the cardinal signs (resting tremor, bradykinesia, rigidity) being present, without any other known or suspected cause of parkinsonism.
Description

idiopathic parkinson

Type de données

boolean

Alias
UMLS CUI [1,1]
C0030567
UMLS CUI [1,2]
C0332240
subjects must experience levodopa related motor fluctuations averaging at least 2.5 hours daily in the off state.
Description

levodopa related motor fluctuations

Type de données

boolean

Alias
UMLS CUI [1,1]
C1868976
UMLS CUI [1,2]
C0023570
subjects must be taking optimized levodopa/carbidopa or levodopa /benserazide carbidopa/levodopa therapy (based on investigator's judgment), stable for at least 14 days prior to baseline. subjects must be receiving at least 3 daily doses of levodopa, not including a bedtime dose.
Description

antiparkinson agents

Type de données

boolean

Alias
UMLS CUI [1]
C0003405
selegiline must be discontinued for at least 90 days prior to baseline.
Description

selegiline

Type de données

boolean

Alias
UMLS CUI [1]
C0036579
subject must be age 30 or older.
Description

age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
subjects must be willing and able to give informed consent.
Description

informed consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects with a clinically significant or unstable medical or surgical condition which would preclude safe and complete study participation. such conditions may include cardiovascular, pulmonary, hepatic, renal, or metabolic diseases or malignancies as determined by medical history, physical exam, laboratory tests, chest x-ray, or ecg for parkinson's disease [e.g., pallidotomy, thalamotomy, and deep brain stimulation (dbs)] within the 12 months preceding the baseline visit.
Description

comorbidity

Type de données

boolean

Alias
UMLS CUI [1]
C0009488
subjects who have undergone neurosurgical transplantation are excluded regardless of when the procedure(s) was performed. no programming changes are permitted in subjects who have undergone dbs.
Description

neurosurgery

Type de données

boolean

Alias
UMLS CUI [1]
C0524850
participation in a previous clinical trial of rasagiline. concomitant therapy with mao inhibitors, reserpine, methyldopa within the past three months, or treatment with an anti-emetic or neuroleptic medication with central dopamine antagonist activity with the past six months.
Description

study subject participation status

Type de données

boolean

Alias
UMLS CUI [1]
C2348568

Similar models

Eligibility Parkinson's Disease NCT00203034

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
idiopathic parkinson
Item
men and women with idiopathic parkinson's disease whose diagnosis is confirmed by at least two of the cardinal signs (resting tremor, bradykinesia, rigidity) being present, without any other known or suspected cause of parkinsonism.
boolean
C0030567 (UMLS CUI [1,1])
C0332240 (UMLS CUI [1,2])
levodopa related motor fluctuations
Item
subjects must experience levodopa related motor fluctuations averaging at least 2.5 hours daily in the off state.
boolean
C1868976 (UMLS CUI [1,1])
C0023570 (UMLS CUI [1,2])
antiparkinson agents
Item
subjects must be taking optimized levodopa/carbidopa or levodopa /benserazide carbidopa/levodopa therapy (based on investigator's judgment), stable for at least 14 days prior to baseline. subjects must be receiving at least 3 daily doses of levodopa, not including a bedtime dose.
boolean
C0003405 (UMLS CUI [1])
selegiline
Item
selegiline must be discontinued for at least 90 days prior to baseline.
boolean
C0036579 (UMLS CUI [1])
age
Item
subject must be age 30 or older.
boolean
C0001779 (UMLS CUI [1])
informed consent
Item
subjects must be willing and able to give informed consent.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
comorbidity
Item
subjects with a clinically significant or unstable medical or surgical condition which would preclude safe and complete study participation. such conditions may include cardiovascular, pulmonary, hepatic, renal, or metabolic diseases or malignancies as determined by medical history, physical exam, laboratory tests, chest x-ray, or ecg for parkinson's disease [e.g., pallidotomy, thalamotomy, and deep brain stimulation (dbs)] within the 12 months preceding the baseline visit.
boolean
C0009488 (UMLS CUI [1])
neurosurgery
Item
subjects who have undergone neurosurgical transplantation are excluded regardless of when the procedure(s) was performed. no programming changes are permitted in subjects who have undergone dbs.
boolean
C0524850 (UMLS CUI [1])
study subject participation status
Item
participation in a previous clinical trial of rasagiline. concomitant therapy with mao inhibitors, reserpine, methyldopa within the past three months, or treatment with an anti-emetic or neuroleptic medication with central dopamine antagonist activity with the past six months.
boolean
C2348568 (UMLS CUI [1])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial